[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-407913-105":59,"doc-detail-407913-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","syndecan-1-as-a-biomarker-for-cardiovascular-risk-in-patients-with-behcets-disease","Syndecan-1 as a Biomarker for Cardiovascular Risk in Patients with Behçet’s Disease","","Study evaluates whether syndecan-1 levels can serve as a biomarker for diagnosing cardiovascular disease and atherosclerosis in patients with Behçet’s disease. After sample-size estimation, 56 patients and 56 age- and sex-matched controls were enrolled. Carotid intima-media thickness (cIMT) was measured by a single radiologist, and syndecan-1 was quantified using a human ELISA kit. Patients showed higher syndecan-1 and cIMT, with a negative association between syndecan-1 and cIMT, suggesting potential relevance to subclinical atherosclerosis progression.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/syndecan-1-as-a-biomarker-for-cardiovascular-risk-in-patients-with-behcets-disease/407913/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/syndecan-1-as-a-biomarker-for-cardiovascular-risk-in-patients-with-behcets-disease/407913.png","ImageObject",300,407,{"name":92,"@type":93},"Dipper","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of measuring syndecan-1 in this study?","Question",{"text":112,"@type":113},"The study assessed whether syndecan-1 levels could function as a biomarker to help diagnose cardiovascular diseases and atherosclerosis in patients with Behçet’s disease.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were participants and key measurements arranged?",{"text":117,"@type":113},"Fifty-six patients with Behçet’s disease and 56 age- and sex-matched controls were enrolled. cIMT was measured by a single radiologist, and syndecan-1 was determined by ELISA.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about syndecan-1 and cIMT?",{"text":121,"@type":113},"Syndecan-1 levels and cIMT were significantly higher in patients than in controls. Correlation analysis found a significant negative relationship between syndecan-1 and cIMT, and regression linked cIMT with age, syndecan-1, and LDL.",{"name":123,"@type":110,"acceptedAnswer":124},"What conclusion did the authors draw and what are the next steps?",{"text":125,"@type":113},"Syndecan-1 was higher in patients and increased syndecan-1 may slow subclinical atherosclerosis progression. The study is preliminary, and further detailed research is needed.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},407913,1790871456,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":46,"preview_page_count":4},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","ORIGINAL ARTICLE  \nArchives of Rheumatology 2025;40(4):435-442 DOI: 10.5152/ArchRheumatol.2025.11178  \nSyndecan-1 as a Biomarker for Cardiovascular Risk in Patients with Behçet’s Disease  \nABSTRACT  \nBackground/Aims: This study aimed to assess the potential of syndecan-1 levels as a biomarker for diagnosing cardiovascular diseases and atherosclerosis in patients with Behçet’s disease.  \nMaterials and Methods: After estimating the required sample size, 56 patients with Behçet’s disease and 56 age- and sex-matched controls were enrolled in the study. Carotid intima-media thickness (cIMT) was measured by a single radiologist using an appropriate technique. Syndecan-1 levels were determined with an Syndecan-1 human ELISA kit (CLOUD CLONE, USCN) . The test system showed a correlation coefficient of 0.99 between expected and actual values, with a detection limit of around 0.01 ng/mL. The intra-assay coefficient of variation (CV) was under 10%, and the inter-assay CV was under 12% .  \nResults: The data obtained from the study showed that syndecan-1 levels (P \u003C .002) and cIMT measurements (P \u003C .015) were significantly higher in patients with Behçet’s disease compared to the healthy control group. Additionally, correlation analysis revealed a significant negative relationship between syndecan-1 levels and cIMT. In a stepwise multiple regression analysis, a strong independent relationship was found between cIMT and age (beta [β] = 0.474, P \u003C .001), syndecan-1 (β = 0.302, P = .007), and low-density lipoprotein (β = 0.219, P = .050) .  \nConclusion: Syndecan-1 levels were higher in patients with Behçet’s disease compared to controls, and increased syndecan-1 may slow the progression of subclinical atherosclerosis. This study is a preliminary investigation. Further detailed studies are needed.  \nKeywords: Atherosclerosis, Behçet di̇sease, cardiovascular risk, sydecan-1,  \ncIMT  \nIntroduction  \nBehçet’s disease is a chronic autoimmune disorder characterized by systemic inflammation, with an unclear etiology and a tendency for vascular involvement. Although it mainly affects the blood vessels, it can also involve multiple organ systems. Key clinical symptoms include eye problems, recurrent mouth ulcers, inflammation of both arteries and veins, arthritis, skin lesions, as well as gastrointestinal and neurological issues.1,2 In patients with Behçet’s disease, an overactive immune response causes widespread systemic inflammatory damage.3 The condition is more common in men than in women and generally follows a more severe course in male patients. It occurs more often in countries along the historic Silk Road, especially in the Middle East and East Asia. Its prevalence in Asian populations ranges from 110 to 120 per 100 000,1,2  \nCopyright@Author(s) -[Available online at archivesof rheumatology.com](Available online at archivesof rheumatology.com). Content of this journal is licensed under a Creative Commons Attribution (CC BY) 4.0 International License.  \nCengiz Kadıyoran1 Pınar Diydem Yılmaz1 Mevlüt Hakan Göktepe2 Adem Küçük3 Mustafa Oğul4  \nErkan Cüre5 Faik Özdengül6  \n1Department of Radiology, Necmettin Erbakan University Medical School, Konya, Türkiye 2Department of Internal Medicine, Necmettin Erbakan University Medical School, Konya, Türkiye 3Department of Rheumatology, Necmettin Erbakan University Medical School, Konya, Türkiye  \n4Department of Internal Medicine, Konya Numune Hospital, Konya, Türkiye  \n5Department of Internal Medicine, Gaziosmanpaşa Medicalpark Hospital, İstinye University, İstanbul, Türkiye  \n6Department of Physiology, Necmettin Erbakan University Medical School, Konya, Türkiye Corresponding author: Cengiz Kadiyoran  \n􀀍 [ckadiyoran@hotmail.com](ckadiyoran@hotmail.com)  \nReceived: March 27, 2025  \nRevision Requested: June 16, 2025 Last Revision Received: September 9, 2025  \nAccepted: September 15, 2025  \nPublication Date: December 1, 2025  \nCite this article as: Kadiyoran C, Diydem Yilmaz P, Hakan Göktepe M, et al. Syndec","cbCaijkyW17iXira","https://ap.wps.com/l/cbCaijkyW17iXira","pdf",482716,"English","# Abstract\n# Introduction\n# Materials and Methods\n# Results\n# Conclusion","[{\"question\":\"What was the purpose of measuring syndecan-1 in this study?\",\"answer\":\"The study assessed whether syndecan-1 levels could function as a biomarker to help diagnose cardiovascular diseases and atherosclerosis in patients with Behçet’s disease.\"},{\"question\":\"How were participants and key measurements arranged?\",\"answer\":\"Fifty-six patients with Behçet’s disease and 56 age- and sex-matched controls were enrolled. cIMT was measured by a single radiologist, and syndecan-1 was determined by ELISA.\"},{\"question\":\"What did the results show about syndecan-1 and cIMT?\",\"answer\":\"Syndecan-1 levels and cIMT were significantly higher in patients than in controls. Correlation analysis found a significant negative relationship between syndecan-1 and cIMT, and regression linked cIMT with age, syndecan-1, and LDL.\"},{\"question\":\"What conclusion did the authors draw and what are the next steps?\",\"answer\":\"Syndecan-1 was higher in patients and increased syndecan-1 may slow subclinical atherosclerosis progression. The study is preliminary, and further detailed research is needed.\"}]","Syndecan-1 as a Biomarker for Cardiovascular Risk in Patients with Behçet’s Disease | PDF",1790576865]